ASP 4070

Drug Profile

ASP 4070

Alternative Names: ASP-4070; CryJ2 -DNA-LAMP; CryJ2 DNA LAMP plasmid vaccine; CryJ2-DNA-lysosomal associated membrane protein plasmid; Japanese red cedar LAMP vaccine; Japanese red cedar pollen allergy immunotherapy - Immunomic; JRC LAMP vax vaccine; JRC-LAMP-vax; JRC2-LAMP-vax; Sugi allergy vaccine

Latest Information Update: 29 Nov 2016

Price : $50

At a glance

  • Originator Immunomic Therapeutics
  • Developer Astellas Pharma; Immunomic Therapeutics
  • Class DNA vaccines; Japanese cedar pollen allergy immunotherapies; Vaccines
  • Mechanism of Action Th1 cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Allergic rhinitis; Tree pollen hypersensitivity
  • No development reported Allergic rhinoconjunctivitis

Most Recent Events

  • 22 Nov 2016 Immunomic Therapeutics has patent protection for LAMP-Vax™ technology in USA
  • 01 Sep 2016 Astellas in collaboration with Immunomic Therapeutics completes a phase-I clinical trial in Tree pollen hypersensitivity in Japan (IM) (NCT02469688)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Allergic rhinoconjunctivitis in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top